Tacrolimus rescue therapy for renal allograft rejection - Five-year experience

被引:90
作者
Jordan, ML
Naraghi, R
Shapiro, R
Smith, D
Vivas, CA
Scantlebury, VP
Gritsch, HA
McCauley, J
Randhawa, P
Demetris, AJ
McMichael, J
Fung, JJ
Starzl, TE
机构
[1] UNIV PITTSBURGH,MED CTR,DEPT SURG,DIV UROL SURG & RENAL TRANSPLANTAT,PITTSBURGH,PA 15213
[2] UNIV PITTSBURGH,MED CTR,DEPT SURG,PITTSBURGH TRANSPLANT INST,PITTSBURGH,PA 15213
关键词
D O I
10.1097/00007890-199701270-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the 5 year period from 7/14/1989 until 5/24/1994, we have attempted graft salvage with tacrolimus conversion in a total of 169 patients (median age 33 years, range 2-75 years) with ongoing rejection on baseline CsA immunosuppression after failure of high dose corticosteroids and/or antilymphocyte preparations to reverse rejection. The indications for conversion to tacrolimus were ongoing, biopsy confirmed rejection in all patients. The median interval to tacrolimus conversion was 2 months (range 2 days to 55 months; mean 4.3+/-2.6 months) after transplantation. All patients had failed high dose corticosteroid therapy and 144 (85%) of the 169 patients had received at least one course of an antilymphocyte preparation plus high dose corticosteroid therapy prior to conversion. Twenty-eight patients (17%) were dialysis-dependent at the time of conversion owing to the severity of rejection. With a mean follow-up of 30.0+/-2.4 months (median 36.5 months, range 12-62 months), 125 of 169 patients (74%) have been successfully rescued and still have functioning grafts with a mean serum creatinine (SCR) of 2.3+/-1.1 mg/dl. Of the 144 patients previously treated with antilymphocyte preparations, 117 (81%) were salvaged. Of the 28 patients on dialysis at the time of conversion to tacrolimus, 13 (46%) continue to have functioning grafts (mean SCR 2.15+/-0.37 mg/dl) at a mean follow-up of 37.3 +/- 16.7 months. In the 125 patients salvaged, prednisone doses have been lowered from 28.0+/-9.0 mg/d (median 32, range 4-60 mg/d) preconversion to 8.5+/-4.1 mg/d (median 12 mg/d, range 2.5-20 mg/d) postconversion. Twenty-eight patients (22.4%) are currently receiving no steroids. This 5 year experience demonstrates that tacrolimus has sustained efficacy as a rescue agent for ongoing renal. allograft rejection. Based on these data, we recommend that tacrolimus be used as an alternative to the conventional drugs used for antirejection therapy in renal transplantation.
引用
收藏
页码:223 / 228
页数:6
相关论文
共 18 条
  • [1] CALNE RY, 1987, LANCET, V2, P506
  • [2] ANALYSES OF THE UNOS-SCIENTIFIC-RENAL-TRANSPLANT-REGISTRY AT 3 YEARS - EARLY EVENTS AFFECTING TRANSPLANT SUCCESS
    CECKA, JM
    CHO, YW
    TERASAKI, PI
    [J]. TRANSPLANTATION, 1992, 53 (01) : 59 - 64
  • [3] MULTICENTER COMPARISON OF TACROLIMUS (FK-506) WHOLE-BLOOD CONCENTRATIONS AS MEASURED BY THE ABBOTT IM(X) ANALYZER AND ENZYME-IMMUNOASSAY WITH METHYLENE-CHLORIDE EXTRACTION
    DAMBROSIO, R
    GIRZAITIS, N
    JUSKO, WJ
    [J]. THERAPEUTIC DRUG MONITORING, 1994, 16 (03) : 287 - 292
  • [4] FREY D, 1991, TRANSPLANTATION, V54, P50
  • [5] GRENIER FC, 1991, TRANSPLANT P, V23, P2748
  • [6] Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity
    Hariharan, S
    Munda, R
    Cavallo, T
    Demmy, AM
    Schroeder, TJ
    Alexander, JW
    First, MR
    [J]. TRANSPLANTATION, 1996, 61 (08) : 1161 - 1165
  • [7] FK506 RESCUE FOR RESISTANT REJECTION OF RENAL-ALLOGRAFTS UNDER PRIMARY CYCLOSPORINE IMMUNOSUPPRESSION
    JORDAN, ML
    SHAPIRO, R
    VIVAS, CA
    SCANTLEBURY, VP
    RHANDHAWA, P
    CARRIERI, G
    MCCAULEY, J
    DEMETRIS, AJ
    TZAKIS, A
    FUNG, JJ
    SIMMONS, RL
    HAKALA, TR
    STARZL, TE
    [J]. TRANSPLANTATION, 1994, 57 (06) : 860 - 865
  • [8] JORDAN ML, 1991, TRANSPLANT P, V23, P3078
  • [9] MATAS AJ, 1993, 19 ANN M AM SOC TRAN
  • [10] SHAPIRO R, 1995, TRANSPLANTATION, V59, P485